ubmslateNT-logo-ubm

NT Mobile Menu

Search form

Topics:

Multiple sclerosis

Predicting Multiple Sclerosis Risk: GEMS Project

By studying first-degree relatives of patients with MS, can researchers perfect a risk algorithm for the disease?

 

© Lightspring/Shutterstock.com

FsdffsdFor people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability.For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability.For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability. - See more at: http://www.neurologytimes.com/multiple-sclerosis#sthash.Aq5cH0PQ.dpuf

MS and Cigarettes: Where There’s Smoke, There’s Disease Progression

For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability.

- See more at: http://www.neurologytimes.com/multiple-sclerosis#sthash.P3SjVoYj.dpuf

For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability.

- See more at: http://www.neurologytimes.com/multiple-sclerosis#sthash.P3SjVoYj.dpuf
For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability. - See more at: http://www.neurologytimes.com/multiple-sclerosis#sthash.Aq5cH0PQ.dpuf

Multiple sclerosis

Three new multiple sclerosis studies show the promise of two drugs, amiselimod and alemtuzumab, as treatments and one, arbaclofen, for spasticity.

Our Sept. news includes a possible clinical marker and therapy target in Alzheimer disease and MS findings from an optical coherence tomography study.

Research presented at this ECTRIMS session covered management of multiple sclerosis-related fatigue, cognitive issues, and gait impairment.

This ECTRIMS session includes studies using 7T and 3T MRI images and translocator protein PET scans, as well as phenotypes in gray matter and more.

Hot Topics session at ECTRIMS 2016: treat early active RRMS with potent induction therapy or immunomodulation then escalation? Where do you stand?

The session featured a study comparing MRI criteria for diagnosing MS, the role of spinal cord volume loss in predicting disease activity, and more.

New research covers treating MS early, identifying those at risk for AED-induced psychosis, & selecting a drug for epilepsy patients with migraines.

Pages

Subscribe to Multiple sclerosis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.